Jazz Pharmaceuticals (JAZZ)
Health Care · Specialty biopharmaceuticals focused on rare disease and oncology
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments.
What Jazz Pharmaceuticals does
Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing life-changing medicines for patients with rare diseases, often with limited or no therapeutic options. The company maintains a diverse portfolio of approved therapies spanning epilepsies, sleep disorders, and cancers, supported by a robust pipeline of innovative programs. Jazz combines patient-focused research and development with an efficient, scalable commercial operating model to reach patients globally.
Themes: ["Epilepsy / seizure disorders","Sleep disorders (narcolepsy, idiopathic hypersomnia)","Rare diseases","Oncology / cancer therapeutics","Cannabinoid therapeutics"]
Fundamentals
- Price$246.91 as of 2026-07-09 close
- Market cap$15.6B as of 2026-07-10
- 1-year return+127.5% as of 2026-07-09 close
- P/E528.28 as of 2026-07-10
- Net margin+0.7% as of 2026-07-10
- Gross margin+88.0% as of 2026-07-10
- ROE+0.7% as of 2026-07-10
- Debt / equity1.18 as of 2026-07-10
- Revenue growth (YoY)+9.2% as of 2026-07-10
- Revenue CAGR (3y)+5.3% SEC XBRL
- Beta0.37 as of 2026-07-10
Key risks (from latest filing)
["Generic competition and ANDA filings from multiple manufacturers (Teva, Padagis, Apotex, InvaGen, Lupin, Taro, Zenara, Biophore, MSN Laboratories, Alkem, and Ascent) targeting Epidiolex could significantly reduce market share and revenues.","Reliance on accelerated approval pathway for newer oncology products (Ziihera, Modeyso, Zepzelca combination approval) with potential for post-market safety or efficacy issues requiring confirmatory trials or withdrawal.","Dependence on controlled-substance distribution regulatory framework and DEA compliance for Xywav and other oxybate-based products creates operational and reputational risks."]
Competitors & peers
- GW Pharmaceuticals (acquired May 2021)
- Axsome Therapeutics
- Alkermes
- Avadel Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Sumitomo Pharma Co., Ltd.
- Chimerix, Inc. (acquired April 2025)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.